Embryo-fetal transfer of bevacizumab (Avastin) in the rat over the course of gestation and the impact of neonatal Fc receptor (FcRn) binding.

@article{Thorn2012EmbryofetalTO,
  title={Embryo-fetal transfer of bevacizumab (Avastin) in the rat over the course of gestation and the impact of neonatal Fc receptor (FcRn) binding.},
  author={Mitchell Thorn and Nicole M Piche-Nicholas and Donald B Stedman and Scott W Davenport and Ning Zhang and Mark Collinge and Christopher John Bowman},
  journal={Birth defects research. Part B, Developmental and reproductive toxicology},
  year={2012},
  volume={95 5},
  pages={363-75}
}
BACKGROUND There is concern about embryo-fetal exposure to antibody-based biopharmaceuticals based on the increase of such therapies being prescribed to women of childbearing potential. Therefore, there is a desire to better characterize embryo-fetal exposure of these molecules. The pregnant rat is a standard model for evaluating the potential consequences… CONTINUE READING